Pre-clinical and Clinical Study Results for the Coracto ™ Rapamycin-eluting Stent - A New-generation Drug-eluting Stent

First- and second-generation drug-eluting stents (DES) have successfully decreased the rate of restenosis compared with bare-metal stents (BMS); however, the incidence of late stent thrombosis, which mostly occurs after the implantation of DES, and chronic restenosis are still important medical problems. A new generation of DES, the Coracto™ rapamycin-eluting stent (RES), has the potential to reduce late stent thrombosis and the risk of chronic restenosis due to the totally biodegradable polymer providing a controlled drug release. In brief, the results of the two pre-clinical studies proved the safety and efficacy of the Coracto RES. In addition, in a clinical study comparing the Coracto RES and the Constant BMS, patients receiving the Coracto RES with chronic total occlusion (CTO) had a 71% decrease in the relative risk of restenosis after six months and an 82% reduction in target vessel revascularisation (TVR) after 24 months. The late stent thrombosis of the Coracto RES was 0% at 24-month follow-up. This article provides an overview of the data obtained from pre-clinical animal experiments using a porcine and rabbit model of stenting and a recently conducted clinical study demonstrating the safety and efficacy of the Coracto RES.

[1]  B. Rangan,et al.  Use of drug‐eluting stents for chronic total occlusions: A systematic review and meta‐analysis , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  K. Hauptmann,et al.  Short and long term comparison (24 months) of an alternative sirolimus-coated stent with bioabsorbable polymer and a bare metal stent of similar design in chronic coronary occlusions: the CORACTO trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  C. Macaya,et al.  Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[4]  J. Abbott,et al.  Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program , 2009, Vascular health and risk management.

[5]  P. Serruys,et al.  Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. , 2009, Circulation. Cardiovascular interventions.

[6]  Barry O'Brien,et al.  The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: a review. , 2009, Acta biomaterialia.

[7]  Sunil V. Rao,et al.  Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. , 2009, JACC: Cardiovascular Interventions.

[8]  A. Kastrati,et al.  A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.

[9]  G. Biondi-Zoccai,et al.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®) , 2008, Vascular health and risk management.

[10]  Jeffrey L. Anderson,et al.  2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  M. Böhm,et al.  Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2006, Clinical research in cardiology : official journal of the German Cardiac Society.

[12]  A Haycox,et al.  Drug-eluting stents: a systematic review and economic evaluation. , 2007, Health technology assessment.

[13]  C. Laurencin,et al.  Biodegradable polymers as biomaterials , 2007 .

[14]  A. Abizaid Sirolimus-eluting coronary stents: a review , 2007, Vascular health and risk management.

[15]  G. Stone,et al.  Clinical ResearchInterventional CardiologyIncidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent: A TAXUS II, IV, V, and VI Meta-Analysis of 3,445 Patients Followed for Up to 3 Years , 2007 .

[16]  P. Serruys,et al.  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  B. Rensing,et al.  Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.

[18]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[19]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  A. Kastrati,et al.  Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. , 2005, European heart journal.

[21]  E. Bramucci,et al.  Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. , 2004, JAMA.

[22]  G. Biondi-Zoccai,et al.  A practical algorithm for systematic reviews in cardiovascular medicine. , 2004, Italian heart journal : official journal of the Italian Federation of Cardiology.

[23]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[24]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[25]  G. Trevi,et al.  Immediate and medium-term outcomes following the treatment of very long (> or =50 mm) chronic total coronary artery occlusions. , 2004, The Journal of invasive cardiology.

[26]  Shile Huang,et al.  Mechanisms of resistance to rapamycins. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  O. Pillai,et al.  Polymers in drug delivery. , 2001, Current opinion in chemical biology.

[28]  P. Mølstad,et al.  Predictors for restenosis after angioplasty of chronic coronary occlusions. , 1998, International journal of cardiology.